Vitiligo

Affiliations

¹ Faculty of Health Sciences (Towheed), McMaster University, Michael G. DeGroote School of Medicine; Faculty of Health Sciences (Cy), McMaster University, Division of Dermatology, Department of Medicine, Hamilton, Ont. shahnawaz.towheed@medportal.ca.

Shahnawaz Towheed. CMAJ. 2025.

. 2025 Mar 2;197(8):E214.

doi: 10.1503/cmaj.240778.

¹ Faculty of Health Sciences (Towheed), McMaster University, Michael G. DeGroote School of Medicine; Faculty of Health Sciences (Cy), McMaster University, Division of Dermatology, Department of Medicine, Hamilton, Ont. shahnawaz.towheed@medportal.ca.

No abstract available

Conflict of interest statement

Competing interests:: None declared.

1. AL-smadi K, Imran M, Leite-Silva VR, et al. . Vitiligo: a review of aetiology, pathogenesis, treatment, and psychosocial impact. Cosmetics 2023;10:84.
1. Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology 2020;236:571–92. - PubMed
1. Seneschal J, Speeckaert R, Taïeb A, et al. . Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international Vitiligo Task Force-Part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol 2023;37:2185–95. - PubMed
1. Rosmarin D, Passeron T, Pandya AG, et al. .; TRuE-V Study Group. Two Phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med 2022;387:1445–55. - PubMed
1. Bibeau K, Ezzedine K, Harris JE, et al. . Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the Global VALIANT study [published erratum in JAMA Dermatol 2024 Jan. 1;160:118]. JAMA Dermatol 2023;159:1124–8. - PMC - PubMed